Melanoma Clinical Trials

90 studies are recruiting for melanoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 3

1. Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma

   This is a phase I/II clinical trial of a single dose of CD40L-augmented TIL administered in patients with advanced melanoma (Cohort 1: Cutaneous acral melanoma, cutaneous non-acral melanoma, (n=26); Cohort 2: Mucosal melanoma, uveal melanoma, (n=10)). Patients will undergo an excision of a readily …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Run by

   H. Lee Moffitt Cancer Center and Research Institute

   See if you can join NCT06961357 on ClinicalTrials.gov

2. Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

   Patients with histologically or cytologically confirmed advanced melanoma, renal cell carcinoma, NSCLC, HCC (Child Pugh Class A only), MSI-High solid tumors, Urothelial Cancer, GE junction/Gastric Adenocarcinoma, or HNSCC for which current standard of care treatment for their stage of disease would…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Run by

   Dan Zandberg

   See if you can join NCT04114136 on ClinicalTrials.gov

3. Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma Patients

   This clinical trial studies how people feel and live during the first two years after being treated for melanoma and whether cognitive behavioral therapy for cancer distress (CBT-C) works to improve quality of life in patients with stage III-IV melanoma. The melanoma survivorship population is rapi…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Mayo Clinic in Rochester, Rochester, Minnesota

   Run by

   Mayo Clinic

   See if you can join NCT07379138 on ClinicalTrials.gov

4. In Vivo Real-time Detection of Circulating Melanoma Cells

   The objective of this clinical trial is to determine whether a Photoacoustic flow cytometry (PAFC)-based prototype device can detect circulating tumor cells (CTCs) in the blood of melanoma patients in vivo, in real time, and do so at detection limits at least one order of magnitude below the detect…

   Stage

   Not phased

   Ages

   18 to 80

   Site

   University of Arkansas for Medical Sciences, Little Rock, Arkansas

   Run by

   University of Arkansas

   See if you can join NCT01776905 on ClinicalTrials.gov

5. Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma

   Melanoma in-transit metastases (ITMs) continue to represent a therapeutic dilemma, in that no standard method of treatment has been uniformly adopted. The complexity and heterogeneity of patient and disease characteristics, including the location and number of ITMs presents a barrier to a one size …

   Stage

   Not phased

   Ages

   18 and older

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Run by

   Yana Najjar

   See if you can join NCT04658303 on ClinicalTrials.gov

6. MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

   This is a multipart, open-label, multi-center dose escalation, dose expansion phase I clinical trial designed to evaluate the safety, tolerability, maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and preliminary efficacy of MEM-288 in patients with advanced solid tumors. Eligible sub…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Locations

   2 in total

   Run by

   Memgen, Inc.

   See if you can join NCT05076760 on ClinicalTrials.gov

7. Evaluation of Hypoxia in Primary Melanoma

   When controlling for tumor present in the Sentinel lymph node (SLN), intranodal hypoxia, as measured by Carbonic Anhydrase IX (CAIX IHC), is associated with worse PFS. This suggests that melanoma tumors may be utilizing deregulated metabolism as a means of propagating themselves to the next station…

   Stage

   Not phased

   Ages

   18 and older

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Run by

   Yana Najjar

   See if you can join NCT06831071 on ClinicalTrials.gov

8. Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma

   This pilot trial studies whether a procedure called lymphovenous bypass would prevent lymphedema (arm swelling) in patients with inflammatory breast cancer or non-inflammatory breast cancer that has spread to nearby tissues or lymph nodes or melanoma. The lymphovenous bypass procedure creates a pat…

   Stage

   Not phased

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT03941756 on ClinicalTrials.gov

9. High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies

   Over the past three decades, the treatment of both primary and secondary liver malignancies has been improved by the development and optimization of multiple minimally invasive thermal ablative therapies. These advances have resulted in a myriad of benefits for patients including decreased morbidit…

   Stage

   Not phased

   Ages

   19 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT05053555 on ClinicalTrials.gov

10. Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

    This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs. Patients will be asked their opinions about the design, accessibility, and content of …

    Stage

    Not phased

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT04751396 on ClinicalTrials.gov

11. B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

    3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells genetically engineered to express B7-H3-CARs for patients ≤ 21 years old, with relapsed/refractory B7-H3+ solid tumors. This study will evaluate…

    Stage

    Phase 1

    Ages

    Up to 21

    Site

    St. Jude Children's Research Hospital, Memphis, Tennessee

    Run by

    St. Jude Children's Research Hospital

    See if you can join NCT04897321 on ClinicalTrials.gov

12. Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

    This is a multicenter, phase II trial of relatlimab (rela), nivolumab (nivo), and ipilimumab (ipi) in patients with asymptomatic and symptomatic melanoma brain metastases.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Stanford University, Palo Alto, California

    Run by

    Stanford University

    See if you can join NCT06712927 on ClinicalTrials.gov

13. A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

    This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe, tolerable, and eff…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    USC Norris Comprehensive Cancer Center, Los Angeles, California

    Locations

    11 in total

    Run by

    Regeneron Pharmaceuticals

    See if you can join NCT06413680 on ClinicalTrials.gov

14. A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

    This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment opti…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

    Locations

    23 in total

    Run by

    Nested Therapeutics, Inc

    See if you can join NCT06326411 on ClinicalTrials.gov

15. Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

    The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

    Run by

    Diwakar Davar

    See if you can join NCT07223424 on ClinicalTrials.gov

16. RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

    This early-phase study will examine Vusolimogene Oderparepvec, a genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities. Upon administration, vusolimogene oderparepvec specifically targets, in…

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

    Run by

    Yana Najjar

    See if you can join NCT06216938 on ClinicalTrials.gov

17. A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

    This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study nea…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Colorado Cancer Center, Aurora, Colorado

    Locations

    5 in total

    Run by

    7 Hills Pharma, LLC

    See if you can join NCT06362369 on ClinicalTrials.gov

18. Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

    The purpose of this study is to determine if neoadjuvant (treatment before surgery) immunotherapy treatment based on tumor biomarkers results in better participant outcomes. Immunotherapy is the treatment of disease by using a person's own immune system. This study is divided into 2 sub-studies/par…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Run by

    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT06295159 on ClinicalTrials.gov

19. Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

    This is a phase 2, single-arm, open label clinical trial determining efficacy of Cyclophosphamide and Pembrolizumab in subjects with melanoma.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Chao Family Comprehensive Cancer Center University of California, Irvine, Orange, California

    Run by

    University of California, Irvine

    See if you can join NCT06771544 on ClinicalTrials.gov

20. Promoting Immunotherapy Efficacy With Low-Dose Liver RT

    The purpose of this study is to see if adding Low-Dose Liver Radiation (LD-LRT) improves progression free survival (PFS). This study is for patients with either melanoma or non-small cell lung cancer (NSCLC), with liver metastases, and receiving immunotherapy.

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Cincinnati Medical Center, Cincinnati, Ohio

    Run by

    Jordan Kharofa

    See if you can join NCT07225036 on ClinicalTrials.gov

21. Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

    Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escala…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT04354064 on ClinicalTrials.gov

22. A Storage Facility for Tissues Obtained From Patients With Malignant Melanoma

    This study collects and stores blood and tumor samples from patients with malignant melanoma and healthy individuals. The purpose of this study is to gain a better understanding of the causes of melanoma and how melanoma tumors behave. Storing blood and tumor samples for future research may lead to…

    Stage

    Not phased

    Ages

    Any age

    Site

    Ohio State University Comprehensive Cancer Center, Columbus, Ohio

    Run by

    Ohio State University Comprehensive Cancer Center

    See if you can join NCT04567706 on ClinicalTrials.gov

23. Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

    This study will examine the impact of anti-programmed cell death 1 (PD1) therapy given in the approved adjuvant therapeutic regimens upon the morphologic, histopathologic, molecular and immunologic as well as genomic features of atypical/dysplastic nevi (A/DN) in patients with a prior documented me…

    Stage

    Not phased

    Ages

    18 and older

    Site

    UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

    Run by

    John Kirkwood

    See if you can join NCT06599619 on ClinicalTrials.gov

24. Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients

    The purpose of this research study is to determine if analysis of PET/CT scans and testing of blood samples in people with melanoma that has spread in their body can help researchers determine which patients are more or less likely to respond to immunotherapy and are more or less likely to have sid…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Wisconsin Hospitals and Clinics (UWHC), Madison, Wisconsin

    Run by

    University of Wisconsin, Madison

    See if you can join NCT06199713 on ClinicalTrials.gov

25. Sample Collection for Ongoing Research and Product Evaluation Study

    The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors. The collected specimens and information will be used to evaluate the clinical performance of Natera's m…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Natera, Inc., Austin, Texas

    Run by

    Natera, Inc.

    See if you can join NCT07318051 on ClinicalTrials.gov